Breast Cancer

New cancer-spreading protein discovered in groundbreaking study.

Breast cancer patients with many social ties have significantly lower rates of death and recurrence.

Patients share their personal stories with Specialty Pharmacy Times.

Metastasis affects as many as 5% of cancer patients around the world.

Cyclin-dependent kinase inhibitor reduces Ki67 expression and shows promise in breast cancer treatment.

Ceritinib (Zykadia) could potentially be used as a first-line treatment in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.

Celgene will continue trials with Abraxane plus immunotherapy drugs.

Celgene will continue trials with Abraxane plus immunotherapy drugs.

Alcohol could cause 7100 annual cancer deaths by 2035.

Research suggests cancer cells may evade treatment by eating adult stem cells.

TIP60 levels could serve as a prognostic marker of breast cancer progression.

The new method makes breast imaging less risky, and can lessen false-positive readings.

About 1 in 6 women diagnosed with breast cancer have a symptom other than a lump.

Women who display non-lump breast cancer symptoms are less likely to seek needed care.

Determining the contents of extracellular vesicles may create targeted treatments.

Tailored dose-dense chemotherapy did not statistically improve recurrence-free survival in breast cancer patients.

Targeting a certain antioxidant protein reduces the aggressiveness of triple-negative breast cancer and increases its sensitivity to conventional anti-cancer drugs.

Promising data on pediatric relapsed/refractory acute lymphoblastic leukemia to be presented.

Ibrance has received approval from the European Commission to treat metastatic breast cancer.

A 2-year study will examine the effectiveness of advanced MRI to determine response to breast cancer treatment.

Rehabilitation with the help of the internet ameliorates life quality and side effects in women with breast cancer.

Having multiple sclerosis may not increase the risk of breast cancer in women.

Ribociclib seeks approval as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

The FDA has accepted Novartis’ New Drug Application (NDA) and granted Priority Review for LEE011 (ribociclib).

Stay up-to-date with the hottest news in pharmacy!